Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study
Authors' conclusion
About one sixth of ICI-IA resolved despite maintaining active ICI treatment and allowing ICI-IA treatment discontinuation without recurrence of symptoms, mainly in those with PMR-like presentation.
Study context
- Population
- ICI-treated patients referred to rheumatology at Bordeaux University Hospital with ICI-induced inflammatory arthritis and follow-up ≥6 months after onset
- Participants
- 80 patients
- Outcome
- Resolution of ICI-IA (discontinuation of ICI-IA medications without recurrence of symptoms) during ICI treatment and after ICI discontinuation
Methodological detailssingle-centre, observational
- Single-centre
- Observational
Main finding
As reported in the abstract
Resolution of ICI-IA while maintaining active ICI treatment
- Resolution of ICI-IA while maintaining active ICI
- 13 of 80 patients (16%)
- Mainly in patients with PMR-like clinical presentation
- P=0.03
Observational data: associations, not effects.
Further findings
Resolution after ICI discontinuation in patients with persistent ICI-IA throughout ICI treatment · 6 and 12 months post-ICI discontinuation
- Resolved at 6 months post-ICI discontinuation
- 34 (50%)
- Resolved at 12 months post-ICI discontinuation
- 47 (70%)
Reason for terminating ICI in those with active ICI-IA at 6 and 12 months post-discontinuation
- More frequently cancer stable or in remission in those with still active ICI-IA
Progression-free survival and overall survival · 6 and 12 months after ICI discontinuation
- Both longer in the groups with active ICI-IA at 6 and 12 months after ICI discontinuation
Original publication
Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study. Joint Bone Spine. Published 22 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →